Delphia Therapeutics

Delphia Therapeutics is a biotechnology company based in Cambridge, Massachusetts, focused on developing new cancer treatments. The company's unique approach, known as "activation lethality," targets a surprising vulnerability in cancer cells: their sensitivity to overactivation of oncogenes. This novel strategy holds the potential to overcome the challenges of drug resistance, a major obstacle in traditional cancer therapies. Delphia's innovative platform integrates tumor genetics, functional genomics, and inhibitor drug resistance studies to identify targets that drive activation lethality.

Delphia is led by a team of experienced oncology drug developers with a proven track record of success. The company has raised significant funding from leading investors, including GV (Google Ventures), Nextech Invest, Polaris Innovation Fund, and Alexandria Venture Investments. Delphia's mission is to advance first-in-class targeted cancer medicines that can provide better and more durable outcomes for patients, particularly where drug resistance is observed. They are dedicated to reimagining cancer treatment and establishing activation lethality as the next wave of oncology therapeutics.

Delphia Therapeutics does not explicitly state any information about job flexibility or remote work options on the website or job posting provided.

Delphia Therapeutics is a biotechnology company committed to pioneering a new field of cancer biology called Activation Lethality. They aim to develop first-in-class targeted cancer medicines that address the persistent problem of drug resistance in cancer treatment. Delphia believes by leveraging the unique vulnerability of cancer cells to oncogene overactivation, they can create more effective and durable treatments for patients, ultimately leading to improved outcomes and a more optimistic future for cancer care.

Delphia Therapeutics promotes a culture of bold, courageous, and collaborative thinking. The company emphasizes a shared sense of purpose and urgency to advance the field of cancer biology and develop innovative therapies. This is reflected in their team of distinguished scientists and company builders who have a proven track record of success. They value a supportive, open, and collaborative environment where individuals can contribute to the company's mission and work together to achieve breakthrough results.

Delphia Therapeutics is committed to building a diverse, equitable, and inclusive workplace. They believe that a diverse team of individuals from various backgrounds, experiences, and perspectives leads to greater innovation, creativity, and problem-solving. Their commitment to DEI is reflected in their hiring practices, mentorship programs, and fostering an environment where everyone feels respected, valued, and empowered to contribute their unique talents.